BNT111 Melanoma vaccine candidate is based upon BioNTech's FixVac platform that targets a fixed combination of mRNA-encoded, tumor-associated antigens with the objective of triggering a strong and precise immune response against cancer.
BioNTech's BNT111 is an intravenous therapeutic cancer vaccine candidate encoding for a fixed set of four cancer-specific antigens optimized for immunogenicity and delivered as an RNA-lipoplex formulation. More than 90% of melanomas in patients express at least one of the four tumor-associated antigens encoded in BNT111 (NY-ESO-1, MAGE-A3, tyrosinase, and TPTE).
BNT111 is one of the most advanced of five clinical-stage FixVac product candidates within BioNTech's development pipeline. The FixVac platform candidates consist of a fixed combination of mRNA-encoded non-mutated antigens shared within specific cancer types. In addition, they feature BioNTech's proprietary RNA-lipoplex delivery formulation, which is designed to enhance stability and translation of the mRNA cargo and specifically target dendritic cells. Thus, the vaccine candidate aims to trigger a strong and precise innate and adaptive immune response against cancer cells overexpressing the respective antigen.
如果能成功，感觉是肿瘤治疗的突破性成就
BNT111 Melanoma Vaccine Description
BNT111 Melanoma vaccine candidate is based upon BioNTech's FixVac platform
that targets a fixed combination of mRNA-encoded, tumor-associated antigens with the objective of triggering a strong and precise immune response
against cancer.
BioNTech's BNT111 is an intravenous therapeutic cancer vaccine candidate
encoding for a fixed set of four cancer-specific antigens optimized for
immunogenicity and delivered as an RNA-lipoplex formulation. More than 90%
of melanomas in patients express at least one of the four tumor-associated
antigens encoded in BNT111 (NY-ESO-1, MAGE-A3, tyrosinase, and TPTE).
BNT111 is one of the most advanced of five clinical-stage FixVac product
candidates within BioNTech's development pipeline. The FixVac platform
candidates consist of a fixed combination of mRNA-encoded non-mutated
antigens shared within specific cancer types. In addition, they feature
BioNTech's proprietary RNA-lipoplex delivery formulation, which is designed to enhance stability and translation of the mRNA cargo and specifically
target dendritic cells. Thus, the vaccine candidate aims to trigger a strong and precise innate and adaptive immune response against cancer cells
overexpressing the respective antigen.